Evaluating the effectiveness and safety of hybrid coronary revascularization
Evaluation of Effectiveness and Safety of Hybrid Coronary Revascularization, a Non-randomized, Prospective, Open-label Registry in Real-world Practice
Asan Medical Center · NCT03788369
This study is testing how well and safely a new heart procedure called hybrid coronary revascularization works for people with multiple blocked arteries, especially those affecting the left side of the heart.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Asan Medical Center (other) |
| Locations | 1 site (Seoul) |
| Trial ID | NCT03788369 on ClinicalTrials.gov |
What this trial studies
This observational study assesses the effectiveness and safety of hybrid coronary revascularization in patients with multivessel coronary artery disease, specifically those involving the left anterior descending artery. The study aims to gather real-world data on patient outcomes following this innovative treatment approach. Participants will be monitored for their recovery and any complications that may arise from the procedure.
Who should consider this trial
Good fit: Ideal candidates are adults aged 20 and older who require hybrid coronary revascularization for multivessel coronary artery disease.
Not a fit: Patients with a life expectancy of one year or less or those who have previously undergone coronary artery bypass grafting may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into improved treatment options for patients with complex coronary artery disease.
How similar studies have performed: While hybrid coronary revascularization is a relatively novel approach, previous studies have shown promising results, indicating potential for success in this area.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 20 and more * Hybrid coronary revascularization due to multivessel coronary artery disease(must include left anterior descending artery) * Written consent Exclusion Criteria: * Previous CABG(coronary artery bypass graft) * Life expectancy ≤1 year
Where this trial is running
Seoul
- Asan Medical Center — Seoul, Korea, Republic of (RECRUITING)
Study contacts
- Study coordinator: Do-yoon Kang, MD
- Email: kdy1218@gmail.com
- Phone: 82-2-3010-1745
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Percutaneous Coronary Revascularization, Coronary Stenosis, Coronary Artery Disease Progression, Coronary Artery Bypass Grafting, Hybrid coronary revascularization